Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.00, $0.01 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $205.7 million versus the consensus estimate of $204.97 million.

GUIDANCE:

Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of $0.01. Myriad Genetics sees FY2025 revenue of $818-828 million, versus the consensus of $822.4 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Galmed's Aramchol shows added cell death in prostate cancer study